Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.

This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.

Inclusion Criteria:

• Diagnosis of relapsing multiple sclerosis
• Active disease
• Greater than or equal to (≥) 2 relapses in prior 2 years or 1 relapse in the year prior to screening and/or ≥1 gadolinium (Gd) enhancing lesion

Exclusion Criteria:

• Treatment with anti-cluster of differentiation 20 (CD20) monoclonal antibody within the last 12 months
• Treatment with alemtuzumab within the last 12 months
• Pregnant or nursing mothers